- Home
- LUCD vs RCEL Comparison
LUCD vs RCEL Comparison
Compare LUCD & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- RCEL
- Stock Information
- Founded
- LUCD 2018
- RCEL N/A
- Country
- LUCD United States
- RCEL United States
- Employees
- LUCD N/A
- RCEL N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RCEL Medical/Dental Instruments
- Sector
- LUCD Health Care
- RCEL Health Care
- Exchange
- LUCD Nasdaq
- RCEL Nasdaq
- Market Cap
- LUCD 140.7M
- RCEL 161.5M
- IPO Year
- LUCD 2021
- RCEL N/A
- Fundamental
- Price
- LUCD $1.26
- RCEL $5.19
- Analyst Decision
- LUCD Strong Buy
- RCEL Strong Buy
- Analyst Count
- LUCD 4
- RCEL 4
- Target Price
- LUCD $3.94
- RCEL $16.50
- AVG Volume (30 Days)
- LUCD 1.2M
- RCEL 287.8K
- Earning Date
- LUCD 08-11-2025
- RCEL 08-07-2025
- Dividend Yield
- LUCD N/A
- RCEL N/A
- EPS Growth
- LUCD N/A
- RCEL N/A
- EPS
- LUCD N/A
- RCEL N/A
- Revenue
- LUCD $4,173,000.00
- RCEL $71,661,000.00
- Revenue This Year
- LUCD $91.46
- RCEL $57.29
- Revenue Next Year
- LUCD $213.42
- RCEL $28.07
- P/E Ratio
- LUCD N/A
- RCEL N/A
- Revenue Growth
- LUCD 39.89
- RCEL 41.35
- 52 Week Low
- LUCD $0.68
- RCEL $5.10
- 52 Week High
- LUCD $1.80
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- LUCD 46.57
- RCEL 29.07
- Support Level
- LUCD $1.21
- RCEL $5.10
- Resistance Level
- LUCD $1.34
- RCEL $6.33
- Average True Range (ATR)
- LUCD 0.08
- RCEL 0.32
- MACD
- LUCD -0.01
- RCEL 0.02
- Stochastic Oscillator
- LUCD 50.00
- RCEL 6.10
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.